Introduction
Postoperative delirium affects up to 40% of older patients after surgery. This condition can lead to longer hospital stays, lasting cognitive issues, and higher chances of death within a year after surgery. Sleep problems after surgery may increase the risk of delirium. However, there are few studies on medications that can improve sleep and prevent delirium. Suvorexant is a medication approved for treating insomnia and may help improve sleep and reduce delirium in older surgical patients. More research is needed to confirm its effectiveness.
About the REPOSE Study
The REPOSE study aims to test the effectiveness of suvorexant in improving sleep and reducing delirium in older patients undergoing non-cardiac surgery. This study is a randomized, double-blinded trial, meaning neither the participants nor the researchers know who receives the medication or a placebo.
Methods
The study will include 130 patients aged 65 and older who are having non-cardiac surgery and will stay in the hospital afterward. Participants will be randomly assigned to receive either 20 mg of suvorexant or a placebo for three nights after surgery. The main goal is to measure total sleep time on the first night after surgery. The severity of delirium will also be assessed.
Ethics and Results Sharing
The study has received ethical approval and will share its findings in a peer-reviewed journal and at academic conferences. Data will be made available on ClinicalTrials.gov.
Measurable Outcomes
The REPOSE study will help define clear goals for improving postoperative care by focusing on sleep quality and delirium severity. This can lead to better health outcomes for older patients after surgery.
AI Tools for Clinical Needs
To enhance patient care based on the findings from the REPOSE study, clinics can select AI solutions tailored to specific healthcare tasks. These tools can help track patient outcomes and improve management strategies.
Implementation
Start with a pilot project to test AI solutions in monitoring and managing postoperative care. Track results to understand the real-world impact of the REPOSE study findings.
Contact Us
For more information on AI solutions in medical management, reach out to us:
Telegram: https://t.me/itinai
LinkedIn: https://www.linkedin.com/company/itinai/
